da Silva B B, dos Santos A R, Pires C G, Lopes-Costa P V
Department of Gynecology, Mastology Division, Hospital Getúlio Vargas, Federal University of Piauí, Piauí, Brazil.
Cell Prolif. 2009 Aug;42(4):506-10. doi: 10.1111/j.1365-2184.2009.00615.x. Epub 2009 May 29.
This study aimed to evaluate the effect of raloxifene on vascular endothelial growth factor (VEGF) expression in breast carcinomas of postmenopausal women.
Sixteen postmenopausal patients with operable stage II, oestrogen receptor-positive, infiltrating ductal breast carcinoma were treated with raloxifene at a dose of 60 mg/day, for a period of 28 days prior to definitive surgery. Tumour size varied from 3 to 5 cm (mean 3.7 cm) and mean age of patients was 61.8 years (range 49-72 years). Tumour samples were obtained by incisional biopsy at the time of diagnosis and again at the time of surgery. Immunohistochemical evaluation of VEGF expression was assessed semiquantitatively based on fraction of stained tumour cells and on intensity of staining. McNemar's test of symmetry was used to evaluate agreement between positive or negative classification of VEGF expression prior to and following raloxifene treatment (P < 0.05).
Fourteen of the 16 patients (88%) were classified as positive for VEGF expression prior to raloxifene treatment, while only 5 (31%) were classified as positive following treatment (P < 0.007).
Raloxifene significantly reduced VEGF expression in these oestrogen receptor-positive breast carcinomas of postmenopausal women.
本研究旨在评估雷洛昔芬对绝经后女性乳腺癌中血管内皮生长因子（VEGF）表达的影响。
16例绝经后II期可手术、雌激素受体阳性浸润性导管癌患者，在确定性手术前28天接受剂量为60mg/天的雷洛昔芬治疗。肿瘤大小为3至5cm（平均3.7cm），患者平均年龄为61.8岁（范围49 - 72岁）。在诊断时通过切口活检获取肿瘤样本，并在手术时再次获取。基于染色肿瘤细胞的比例和染色强度对VEGF表达进行免疫组织化学半定量评估。采用McNemar对称性检验评估雷洛昔芬治疗前后VEGF表达阳性或阴性分类之间的一致性（P < 0.05）。
16例患者中有14例（88%）在雷洛昔芬治疗前VEGF表达分类为阳性，而治疗后只有5例（31%）分类为阳性（P < 0.007）。
雷洛昔芬显著降低了这些绝经后女性雌激素受体阳性乳腺癌中的VEGF表达。
Zotero 插件